Date：Friday, July 28, 2023
Andrew Lin is the Chairman of TaiRx, Inc., BRIM Biotechnology Inc. and Nuwa Biomedical. Mr. Lin also serve as an Independent Board of Director for Fubon Life Insurance. Before joining TaiRx, Mr. Lin was the Chairman of Lotus Pharmaceutical, the largest generic drug company listed on Taiwan Stock Exchange. Previously Mr. Lin was the Chief Executive Officer of Hasumi Biotechnology International, a global leader in cancer vaccines and immunotherapy.
Prior to his biotech career, Mr. Lin was the Chief Strategy Office for Chicony Electronics/Clevo Group, a world- renowned Taiwanese electronic components producer and distributor. Preceding Chicony/Clevo, Mr. Lin was a Managing Director with Macquarie Capital, directing its investment banking businesses in the Greater China region, and the Country Head overseeing Macquarie Group’s overall operations in Taiwan. Before joining Macquarie, Mr. Lin was the Chief Financial Officer for Lite-On Technology Group, a US$10 billion technology giant, headquartered in Taiwan.
Preceding his corporate executive roles, Mr. Lin was the Chief Investment Officer for ABN AMRO Asset Management Taiwan. Previous to managing ABN AMRO Taiwan’s US$4.0 billion investment portfolio, Mr. Lin was the Head of Asia Pacific Technology Research for J.P. Morgan Securities and the General Manager for J.P. Morgan Securities Taiwan.
Before his sell-side and buy-side posts, Mr. Lin worked for management consulting firms, McKinsey & Company and Booz • Allen & Hamilton, in both Asia Pacific and the United States.
Prior to his management consulting career, Mr. Lin worked for AT&T Bell Laboratories, Prime Computer and Digital Equipment Corporation in the United States in research and development capacity.
Mr. Lin received his MBA degree from The University of Chicago, Graduate School of Business. He also graduated with an M.S. degree in electrical and computer engineering from the University of Massachusetts at Amherst.